Gcg - glucagon Gene

Also Known as Glp1; GLP-1

Species: Rattus norvegicus

Gene Type: protein coding
Gene ID: 24952

Summary

Enables Glucagon Receptor binding activity and hormone activity. Involved in adenylate cyclase-modulating G protein-coupled receptor signaling pathway; negative regulation of appetite; and response to L-arginine. Located in extracellular space. Human ortholog(s) of this gene implicated in Alzheimer's disease and prediabetes syndrome. Orthologous to human GCG (glucagon). [provided by Alliance of Genome Resources, Apr 2022]

Gcg Products (1)

mRNA Protein Name
NM_012707.3 NP_036839.2 pro-glucagon preproprotein

Gene Ontology

  • Molecular Function
  • Biological Process
  • Cellular Component
Molecular Function GO Annotation Evidence References Source
enables glucagon receptor binding IDA
IDA: Inferred from direct assay
12960094 RGD
enables hormone activity IDA
IDA: Inferred from direct assay
12960094 RGD
enables hormone activity IMP
IMP: Inferred from mutant phenotype
11557638 RGD
Biological Process GO Annotation Evidence References Source
involved in adenylate cyclase-modulating G protein-coupled receptor signaling pathway IDA
IDA: Inferred from direct assay
12960094 RGD
involved in negative regulation of appetite IMP
IMP: Inferred from mutant phenotype
11557638 RGD
involved in response to L-arginine IEP
IEP: Inferred from expression pattern
2182011 RGD
Cellular Component GO Annotation Evidence References Source
located in extracellular space IDA
IDA: Inferred from direct assay
12876072 RGD
EXP: Inferred from Experiment IDA: Inferred from direct assay IPI: Inferred from physical interaction IMP: Inferred from mutant phenotype IGI: Inferred from genetic interaction IEP: Inferred from expression pattern
Protein Preferred Names Protein Names

pro-glucagon

  • glucagon-like peptide-1

Related Agents

  • Approval
  • Clinical Phase
  • Pre-clinical Phase

Approval

Bioactive Molecules (1)
Cat. No. Product Name Effect
Purity Rare Diseases
HY-109556 Insulin Detemir Activator 95.0% Unkown

Clinical Phase

Bioactive Molecules (3)
Cat. No. Product Name Effect
Purity Phase
HY-132596 Tivanisiran Inhibitor 97.48% Phase 3
HY-118874 Oblimersen / Phase 3
HY-109528 Fomivirsen sodium Inhibitor 99.71% Phase 2

Pre-clinical Phase

Bioactive Molecules (14)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-150738 ODN 2088 Antagonist 98.82% Unkown
HY-150743 ODN 2395 Agonist 98.39% Unkown
HY-150217 CpG ODN 10101 Agonist 99.44% Unkown
HY-150736 ODN 20844 Inhibitor 96.14% Unkown
HY-148100 Emapticap pegol Inhibitor 91.38% Unkown
HY-150739 ODN 21158 Inhibitor 98.16% Unkown
HY-150748 ODN D-SL01 Agonist 99.94% Unkown
HY-P5074 GRPP (human) Agonist 98.94% Unkown
HY-148412 Monarsen Inhibitor / Unkown
HY-150213 ODN BW001 Inhibitor / Unkown
HY-171338 Gallocatechin-3-O-(3″-O-methyl)-gallate Inhibitor / Unkown
HY-RS05323 GCG Human Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS17156 Gcg Mouse Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS23606 Gcg Rat Pre-designed siRNA Set A Pre-designed Set / Unkown

Orthologs Information

Species Symbol Source ID
Homo sapiens Gcg NCBI NCBI:2641